Christine Engle
Nurse Practitioner · Merrillville, INNPI 1710512207
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,212 of the $9,573 with a category attached, or 75.3%. 54 manufacturers reported payments, led by Novartis at 30.5% of the total. 2025 is the largest year on record at $3,997, 8.4 times the $477 reported in 2021. Among nurse practitioner clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 325 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- AstraZeneca$691
- E.r. Squibb & Sons, L.L.C.$527
- Pfizer$427
- Johnson & Johnson$379
- AbbVie$366
- plus $4K from 48 others
What the payments were for
- Food & beverage$7,21275%
- Education$1982%
- Other$2,16423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,573 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 39 | $664,239 |
| XtandiEnzalutamide | 33 | $458,027 |
| PomalystPomalidomide | 15 | $343,152 |
| BrukinsaZanubrutinib | 15 | $220,026 |
| TagrissoOsimertinib Mesylate | 14 | $213,528 |
| Lenalidomide | 13 | $205,783 |
| EliquisApixaban | 74 | $68,021 |
| XareltoRivaroxaban | 47 | $37,752 |
| OxycontinOxycodone Hcl | 16 | $8,337 |
| Ondansetron Hcl | 55 | $7,152 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 158 | $4,889 |
| Exemestane | 13 | $3,407 |
| Fentanyl | 21 | $2,153 |
| Anastrozole | 115 | $2,112 |
| Morphine Sulfate ErMorphine Sulfate | 46 | $1,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $2,919 | $664,23939 claims |
| Astellas Pharma US IncXtandi | $117 | $458,02733 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $527 | $343,15215 claims |
| AstraZenecaTagrisso | $691 | $213,52814 claims |
| PfizerEliquis | $427 | $68,02174 claims |
| Johnson & JohnsonXarelto | $379 | $37,75247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Merrillville
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
- Rhonda HettingerClarksville$38K
- Jennifer MaahsIndianapolis$36K
- Amber MillerLawrenceburg$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.